chartexchange

PROK
ProKidney Corp. Class A
stockNASDAQ

Market OpenNov 16, 2026 2:49:52 PM EST
1.03USD-1.435%(-0.02)1,448,995
Pre-marketNov 16, 2026 9:04:30 AM EST
1.02USD-2.392%(-0.02)
1.0300Bid1.0400Ask0.0100Spread
Loading…
Loading…
216.29M
Healthcare
Biotechnology
HQ
Winston-Salem, NC, USA
Previous Close
$1.05
Beta
1.82
52-Week High
$2.65 2025-12-05
52-Week Low
$0.87 2026-11-02
SMA 50
$1.53
SMA 200
$1.76
Avg. Vol 10D
1.74M
Avg. Vol 30D
1.33M
Avg. Vol 90D
1.32M
Relative Vol
1.08
208.98M
108.81M
24,336,295
6.9000%
3,300,000
292,465
PROK Profile

prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney's lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.

PROK Performance
PeriodPriceDateChangeBeta
1W1.152026-11-09-10.00%3.245
1M1.332026-10-16-22.18%2.047
3M1.402026-08-17-26.07%1.824
6M1.662026-05-15-37.65%1.470
1Y2.252025-11-17-54.00%1.819
2Y1.702024-11-15-38.94%—
5Y8.752022-07-13-88.17%1.763
PROK Stock Summary

ProKidney Corp. Class A (NASDAQ:PROK) stock price today is $1.04, and today's volume is 1,443,236. PROK is down 0.957% today. The 30 day average volume is 1.33M. PROK market cap is $216.29M with 208.98M shares outstanding.